Osmotica Pharma (OSMT) Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 for Acquired Blepharoptosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Stocks close lower as Middle East tensions, Treasury yields weigh
- Apple’s iPhone shipments dip 10% in Q1 as Samsung reclaims the top spot
- Tesla (TSLA) to cut over 10% global staff - Electrek
- Aluminum, Nickel, Copper: LME ban on Russian metal creates buying opportunity?
- Informatica (INFA) jumps as Salesforce (CRM) reportedly eyes new mega takeover
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 (“RVL”) for Acquired Blepharoptosis (ptosis or droopy eyelid)
May 6, 2019 4:30 PM EDT- Second Phase III Study 202 Meets Primary Endpoint; Provides Additional Evidence of Efficacy and Safety -
- Long-term Phase III Study 203 Provides Additional Evidence of Safety -
- Company to Host Conference Call on Tuesday, May 7th at 12pm ET with Dr. Chuck Slonim and Dr. Shane Kannarr -
BRIDGEWATER, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Osmotica or the Company) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced positive topline results of its second Phase III... More
Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 (“RVL”) for Acquired Blepharoptosis (ptosis or droopy eyelid)
May 6, 2019 4:30 PM EDT- Second Phase III Study 202 Meets Primary Endpoint; Provides Additional Evidence of Efficacy and Safety -
- Long-term Phase III Study 203 Provides Additional Evidence of Safety -
- Company to Host Conference Call on Tuesday, May 7th at 12pm ET with Dr. Chuck Slonim and Dr. Shane Kannarr -
BRIDGEWATER, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Osmotica or the Company) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced positive topline results of its second... More
